Thermo Fisher Scientific Inc. has completed its acquisition of Mesa Biotech, Inc., a privately held point-of-care molecular diagnostic company.   Mesa Biotech has developed the Accula System, a point-of-care PCR-based testing platform for infectious disease diagnosis. The platform enables rapid, highly accurate testing at physician offices, pharmacies and other settings, providing results in 30 minutes. Beyond COVID-19 testing, Mesa Biotech’s existing platform includes tests for flu, res...